title: [A long-term survival case of local recurrence of breast cancer treated with combined modality therapy].
abstract: The case was a 70-year-old woman. In 1997, the patient underwent pectoral muscle-preserving mastectomy and axillary/subclavicular lymph node dissection for the treatment of right breast cancer. Histological diagnosis was invasive ductal carcinoma (T2, N2, M0, Stage IIIA). She received a combination therapy with TAM and UFT for 5 years postoperatively. Because tumor recurrence occurred in right axillary lymph nodes in the 9th postoperative year, the patient underwent resection of these lymph nodes followed by 6 cycles of AC-based chemotherapy. Multiple lung metastases occurred in the 10th postoperative year, and then, the patient received 8 cycles of DOC-based chemotherapy. In the 11th postoperative year, a mass appeared again in the right axilla, and 6 cycles of capecitabine-based chemotherapy was administered. In the 12th postoperative year, pulmonary metastasis was in progression and an increased right axillary mass were noted. Thus, the specimen extirpated in 2006 was examined again, revealing negative ER, negative PgR and positive HER2. Six cycles of combined trastuzumab+PTX therapy were administered. Lung metastasis decreased in size, allowing a judgment of partial response. Because the right axillary mass had grown to 10 cm, and the patient's QOL was reduced, it was extirpated. The patient is scheduled to receive a postoperative radiotherapy, followed by resumption of chemotherapy.
authors.affiliation: Dept. of Surgery, Hasuda Hospital.
authors.forename: Eriko
authors.initials: E
authors.lastname: Katsuta
authors.forename: Takehiko
authors.initials: T
authors.lastname: Ohkubo
authors.forename: Yasunori
authors.initials: Y
authors.lastname: Someno
authors.forename: Morihito
authors.initials: M
authors.lastname: Saguchi
authors.forename: Haruhiko
authors.initials: H
authors.lastname: Aoyagi
authors.forename: Tarou
authors.initials: T
authors.lastname: Takahata
authors.forename: Kumi
authors.initials: K
authors.lastname: Hasegawa
authors.forename: Setsuo
authors.initials: S
authors.lastname: Hamada
authors.forename: Jun
authors.initials: J
authors.lastname: Kaneko
authors.forename: Shizuaki
authors.initials: S
authors.lastname: Maejima
mesh_terms: D000368:Aged; D000911:Antibodies, Monoclonal / Q000008:administration & dosage; D061067:Antibodies, Monoclonal, Humanized; D000964:Antimetabolites, Antineoplastic / Q000008:administration & dosage; D000970:Antineoplastic Agents / Q000008:administration & dosage; D018931:Antineoplastic Agents, Hormonal / Q000008:administration & dosage; D000972:Antineoplastic Agents, Phytogenic / Q000008:administration & dosage; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage; D001943:Breast Neoplasms / Q000628:therapy*; D018270:Carcinoma, Ductal, Breast / Q000628:therapy*; D003131:Combined Modality Therapy; D000077143:Docetaxel; D005260:Female; D006801:Humans; D008197:Lymph Node Excision; D008408:Mastectomy; D009364:Neoplasm Recurrence, Local; D017239:Paclitaxel / Q000008:administration & dosage; D013629:Tamoxifen / Q000008:administration & dosage; D043823:Taxoids / Q000008:administration & dosage; D005641:Tegafur / Q000008:administration & dosage; D000068878:Trastuzumab; D014498:Uracil / Q000008:administration & dosage
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000964:Antimetabolites, Antineoplastic; D000970:Antineoplastic Agents; D018931:Antineoplastic Agents, Hormonal; D000972:Antineoplastic Agents, Phytogenic; D043823:Taxoids; D013629:Tamoxifen; D005641:Tegafur; D000077143:Docetaxel; D014498:Uracil; D000068878:Trastuzumab; D017239:Paclitaxel